FDA to Expand High Performance Computing to Boost Clinical Trial Efficiency

Drug Industry Daily
A A
The FDA plans to expand its capabilities in high performance computing to help build disease models and simulate clinical trials — as well as establish a new framework for regenerative medicine this fall — as part of an agency “innovation initiative” announced Friday by Commissioner Scott Gottlieb.

To View This Article:

Login

Subscribe To Drug Industry Daily